Latest Healthcare and Pharma Press Release | Latest Healthcare News
Authera lands collaborative agreement with argenx – Inven2
argenx Announces U.S. Food and Drug Administration Approval
Generalized Myasthenia Gravis Market and Epidemiology 2032:
SEC Filing | argenx
Myasthenia Gravis Foundation of America, Inc. - argenx announces positive topline results from Phase 3 ADAPT trial for gMG. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia
argenx | News
Argenx gets FDA nod for first subcutaneous gMG therapy | pharmaphorum
argenx | News
ARGENX SE Form 6-K Current Report Filed 2023-01-09
Argenx Follows up Phase III Success with Giant €785M Global Offering
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy | Argenx
Genmab enters multiyear antibody partnership with Argenx — MedWatch
FUJIFILM Diosynth Biotechnologies enters into an Agreement with Argenx
ITP Support Association - Press release from argenx, they are evaluating: Efgartigimod in ITP: Phase 3 ADVANCE registrational trial initiated evaluating approximately 150 primary ITP patients dosed with 10mg/kg IV efgartigimod for
ARGENX SE - VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Press Releases | Argenx
Argenx: Next Phase Of Growth With Efgartigimod And ARGX-117 (NASDAQ:ARGX) | Seeking Alpha
Corporate Presentation June 2023
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis | Business Wire
ARGENX SE Form 6-K Current Report Filed 2023-01-09
argenx Receives the EMA's CHMP Positive Opinion of Efgartigimod for Generalized Myasthenia Gravis
